QUEST DIAGNOSTICS INC【DGX】
時価総額
$228.1億
PER
臨床検査・診断情報サービスの米国最大手。幅広い検査メニューとデータ駆動の診断ITソリューションを展開。2023年に腫瘍検査企業を3.92億ドルで買収、2024年に病院系ラボを計6.83億ドルで買収。米国中心にカナダも含め全国展開、90%超の被保険者にアクセス。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Net income | 757 | 506 | 592 | 883 | 592 | 753 | 696 | 824 | 788 | 906 | 1,499 | 2,080 | 1,015 | 908 | 921 |
| Depreciation and amortization | 254 | 281 | 287 | 283 | 314 | 304 | 249 | 270 | 309 | 329 | 361 | 408 | 437 | 439 | 493 |
| Provision for credit losses | 292 | 280 | 269 | 270 | 296 | 297 | 308 | 315 | 6 | 11 | 19 | 4 | 3 | 1 | 5 |
| Deferred Income Tax Expense (Benefit) | -19 | 29 | 7 | 19 | 23 | 112 | 37 | 9 | 73 | 15 | 85 | -57 | 1 | -49 | 13 |
| Stock-based compensation expense | 54 | 72 | 50 | 28 | 51 | 52 | 69 | 79 | 61 | 56 | 97 | 79 | 77 | 77 | 88 |
| Other, net | - | -9 | 8 | -2 | 12 | -6 | 6 | 6 | -8 | 39 | 81 | 63 | -66 | -41 | -15 |
| Accounts receivable | - | - | - | - | 312 | 262 | 343 | 298 | 65 | 63 | 455 | -81 | -246 | 15 | 71 |
| Accounts payable and accrued expenses | 18 | -18 | -13 | -21 | 68 | -31 | 56 | -8 | -19 | 73 | 452 | 35 | -149 | -55 | -67 |
| Income taxes payable | 34 | 39 | 101 | -93 | -84 | -41 | 42 | 16 | 4 | 29 | 22 | -20 | -31 | -2 | 16 |
| Other assets and liabilities, net | 16 | -15 | 8 | 11 | -2 | 41 | -25 | 26 | -31 | 4 | 37 | 9 | -53 | 73 | 79 |
| Net cash provided by operating activities | 1,118 | 895 | 1,187 | 652 | 938 | 810 | 1,069 | 1,175 | 1,200 | 1,243 | 2,005 | 2,233 | 1,718 | 1,272 | 1,334 |
| Business acquisitions, net of cash acquired | - | 1,299 | 51 | 213 | 728 | 67 | 139 | 581 | 421 | 58 | 330 | 331 | 144 | 611 | 2,164 |
| Capital expenditures | 205 | 162 | 182 | 231 | 308 | 263 | 293 | 252 | 383 | 400 | 418 | 403 | 404 | 408 | 425 |
| Other investing activities, net | 11 | -3 | -16 | -2 | -11 | -1 | -10 | -2 | -1 | 44 | 27 | 3 | -5 | 42 | -41 |
| Net cash used in investing activities | -217 | -1,243 | -217 | 328 | -1,025 | -362 | -152 | -805 | -801 | -411 | -772 | 21 | -543 | -1,061 | -2,548 |
| Proceeds from borrowings | - | - | 715 | 896 | 2,018 | 2,453 | 1,869 | 205 | 2,090 | 2,281 | 749 | - | - | 2,592 | 1,846 |
| Repayments of debt | -169 | -1,710 | 1,369 | 900 | 1,647 | 2,537 | 1,724 | 182 | 1,966 | 1,449 | 1,554 | 2 | 2 | 1,844 | 303 |
| Purchases of treasury stock | 750 | 935 | 200 | 1,037 | 132 | 224 | 590 | 465 | 322 | 353 | 325 | 2,199 | 1,408 | 275 | 151 |
| Exercise of stock options | 49 | 137 | 162 | 138 | 78 | 60 | 73 | 130 | 99 | 119 | 189 | 129 | 123 | 72 | 73 |
| Employee payroll tax withholdings on stock issued under stock-based compensation plans | - | - | - | - | - | - | 10 | 23 | 21 | 16 | 15 | 22 | 28 | 28 | 24 |
| Dividends paid | 71 | 65 | 108 | 185 | 187 | 212 | 223 | 247 | 266 | 286 | 297 | 309 | 305 | 314 | 331 |
| Distributions to noncontrolling interest partners | 37 | 36 | 38 | 32 | 31 | 42 | 41 | 51 | 54 | 54 | 58 | 99 | 73 | 57 | 47 |
| Other financing activities, net | -8 | -22 | 12 | 10 | -7 | -22 | -45 | 40 | 23 | -17 | 44 | -38 | -39 | 14 | 21 |
| Net cash provided by (used in) financing activities | -986 | 64 | -822 | -1,106 | 92 | -507 | -691 | -592 | -401 | 225 | -1,267 | -2,540 | -1,732 | 160 | 1,084 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7 |
| Net change in cash and cash equivalents and restricted cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 371 | -137 |